argenx (NASDAQ: ARGX) net sales jump 54% as pipeline milestones stack up

What happened

argenx SE (NASDAQ: ARGX) said third-quarter 2026 global product net sales reached $1.7 billion, up 54% from a year earlier.

Product net sales were $1.72 billion in the quarter, versus $1.13 billion in the same period of 2025.

That was a $594 million increase from Q3 2025.

The company reported operating profit of $486 million and profit for the period of $506 million.

Cash, cash equivalents and current financial assets were $3.7 billion at September 30, 2026.

Management said the sBLA for VYVGART Hytrulo in IMNM is on track for submission by year-end 2026.

The filing says that plan is supported by Breakthrough Therapy Designation.

Management said combined R&D and SG&A expenses are now expected to be approximately $4 billion for 2026.

The company said that outlook includes Forte transaction-related costs.

The update also said pediatric gMG has FDA priority review with a February 2027 target action date.

Phase 3 MMN data for empasiprubart are expected in December 2026.

FB102 is moving to Phase 3 in celiac disease.

Key numbers

Metric	Latest	Change	Source
Global product net sales, Q3 2026	$1.7 billion	from $1.13 billion, +54%	Q3 2026 earnings press release
Operating profit, Q3 2026	$486 million	from $346 million, +40.5%	Q3 2026 earnings press release
Profit for the period, Q3 2026	$506 million	from $344 million, +47.1%	Q3 2026 earnings press release
Cash, cash equivalents and current financial assets	$3.7 billion	from $4.4 billion, -$700 million	Q3 2026 earnings press release
2026 combined R&D and SG&A outlook	approximately $4 billion		Q3 2026 earnings press release

Read more: argenx (ARGX) stock analysis and investment case

Why it matters

OptimistFi's case is that VYVGART can expand from a single franchise into a durable immunology platform.

This filing supports that view with higher Q3 product net sales and several near-term clinical and regulatory milestones.

The quarter showed $594 million more product net sales than a year ago, and that helped drive the operating profit and profit figures.

The release still says VYVGART is the foundation of the business.

It also says the next wave of programs still needs clinical and regulatory validation.

The approximately $4 billion 2026 spending outlook shows the company is still funding development, commercialization and the Forte acquisition.

The profit figures point to operating leverage in the current franchise.

The pipeline readouts still determine whether the broader platform story holds.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

Management is scheduled to host a conference call today at 2:30 PM CET (8:30 AM ET).

The next dated tests are Phase 3 EMPASSION topline results in December 2026 and the February 2027 FDA target action date for pediatric gMG.

The company is also scheduled to report full-year 2026 results on February 25, 2027.

Management said the sBLA submission for VYVGART Hytrulo in IMNM is on track for year-end 2026.

Timely submission and supportive data would reinforce the multi-indication case.

Weak MMN data or a delayed regulatory decision would slow that story.

More from OptimistFi

• ARGX stock: the argenx thesis, its status and the next test to watch
• Stock research on every company OptimistFi covers

From OptimistFi Perps